TY - JOUR
T1 - Rosacea management
T2 - A comprehensive review
AU - Sharma, Anuj
AU - Kroumpouzos, George
AU - Kassir, Martin
AU - Galadari, Hassan
AU - Goren, Andy
AU - Grabbe, Stephan
AU - Goldust, Mohamad
N1 - Publisher Copyright:
© 2022 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
PY - 2022/5
Y1 - 2022/5
N2 - Rosacea is a chronic cutaneous disorder affecting primarily the face, characterized by erythema, transient or persistent, telangiectasia, and inflammatory lesions including papulo-pustules and swelling. The essential component of the disease is the persistent erythema of facial skin. Episodes of flushing (acute-subacute intermittent vasodilation) are common. Swelling and erythema of the nose along with dilatation of the pilosebaceous poral orifices, known as rhinophyma, can be noted in chronic cases. Rosacea affects up to 10% of the world population and is especially noted in fair-skinned individuals aged 35–50. Women are affected more often than men. Several treatment modalities including topical medications, systemic drugs, lasers, and light-based therapies have been used for the management of rosacea with variable results. Topical medications such as azelaic acid, metronidazole, and sulfacetamide/sulfur, oral antibiotics such as tetracyclines, and oral retinoids alone or, most commonly, in combination form the mainstay of treatment. Light therapies such as intense pulsed light and pulsed dye laser are best used for the erythemato-telangiectatic type. Topical brimonidine, oxymetazoline, ivermectin, tacrolimus, pimecrolimus, low-dose modified-release tetracyclines and botulinum toxin are the new additions to the therapeutic armamentarium. This article provides a comprehensive review of the various therapies used for rosacea.
AB - Rosacea is a chronic cutaneous disorder affecting primarily the face, characterized by erythema, transient or persistent, telangiectasia, and inflammatory lesions including papulo-pustules and swelling. The essential component of the disease is the persistent erythema of facial skin. Episodes of flushing (acute-subacute intermittent vasodilation) are common. Swelling and erythema of the nose along with dilatation of the pilosebaceous poral orifices, known as rhinophyma, can be noted in chronic cases. Rosacea affects up to 10% of the world population and is especially noted in fair-skinned individuals aged 35–50. Women are affected more often than men. Several treatment modalities including topical medications, systemic drugs, lasers, and light-based therapies have been used for the management of rosacea with variable results. Topical medications such as azelaic acid, metronidazole, and sulfacetamide/sulfur, oral antibiotics such as tetracyclines, and oral retinoids alone or, most commonly, in combination form the mainstay of treatment. Light therapies such as intense pulsed light and pulsed dye laser are best used for the erythemato-telangiectatic type. Topical brimonidine, oxymetazoline, ivermectin, tacrolimus, pimecrolimus, low-dose modified-release tetracyclines and botulinum toxin are the new additions to the therapeutic armamentarium. This article provides a comprehensive review of the various therapies used for rosacea.
KW - IPL
KW - PDL
KW - brimonidine
KW - doxycycline
KW - rosacea
UR - http://www.scopus.com/inward/record.url?scp=85124615800&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124615800&partnerID=8YFLogxK
U2 - 10.1111/jocd.14816
DO - 10.1111/jocd.14816
M3 - Review article
C2 - 35104917
AN - SCOPUS:85124615800
SN - 1473-2130
VL - 21
SP - 1895
EP - 1904
JO - Journal of Cosmetic Dermatology
JF - Journal of Cosmetic Dermatology
IS - 5
ER -